INSIST! Multiple Myeloma
December 2025
Insist! on Better Care
Biomarker testing in multiple myeloma is essential to ensure patients are receiving the best, most personalized care available. The goal of INSIST! Multiple Myeloma is to educate and empower patients and care partners to speak up and insist on better care.
Program topics include:
Personalize Your Experience!
Create an account to save items and receive information curated just for you.
Understanding Testing in Multiple Myeloma
Self-Advocacy | Why In-Depth Cancer Testing Is Essential
December 5, 2025
Molecular Testing and Hereditary Testing: What’s the Difference?
December 5, 2025
When Should Someone With Cancer Undergo Molecular Testing?
November 6, 2025
What Is Molecular Testing and Why Is It Necessary in Cancer Care?
November 6, 2025
What Experts Are Learning About the Hereditary Risk of Myeloma
December 12, 2022
What Should Patients Know About Myeloma Testing?
December 12, 2022
Advances in Myeloma Molecular Testing
October 31, 2022
How Do Test Results Impact Myeloma Treatment Options?
September 30, 2022
Questions to Ask Your Doctor About Essential Myeloma Testing
December 6, 2021
What Do Myeloma Test Results Reveal About Prognosis and Treatment?
December 6, 2021
Which Tests Are Essential to Diagnose and Treat Myeloma?
December 6, 2021
How Does Essential Testing Affect Myeloma Care and Treatment?
December 2, 2021
What Should You Ask Your Doctor About Myeloma Testing?
October 28, 2021
How Is Minimal Residual Disease (MRD) Testing Used in Myeloma Care?
October 28, 2021
How Are Cytogenetics Used in Myeloma Care?
October 28, 2021
How Does Myeloma Testing Affect Care and Treatment?
October 20, 2021
What Standard Testing Follows a Myeloma Diagnosis?
March 31, 2021
Multiple Myeloma Treatment Decisions
How Close Is Personalized Medicine for Myeloma?
May 5, 2023
How Are Myeloma Patients in Remission Monitored?
May 4, 2023
Expert Perspective: COVID Vaccines and Treatment for Myeloma Patients
December 12, 2022
How Is Myeloma Treatment Response Measured?
December 12, 2022
Which Myeloma Patients Are Candidates for CAR T-Cell Therapy?
December 12, 2022
How Is Relapsed or Refractory Myeloma Managed?
December 12, 2022
How Are Patients on Myeloma Maintenance Therapy Monitored?
December 12, 2022
How Is Research Advancing Myeloma Treatment and Care?
December 12, 2022
What Are Currently Available Myeloma Treatments?
December 12, 2022
Understanding Personalized Medicine for Myeloma
December 12, 2022
How Is MGUS Monitored?
December 12, 2022
Understanding MGUS & Smoldering Myeloma: What’s the Difference?
December 12, 2022
Expert Advice for Navigating Myeloma Treatment and Care Decisions
November 16, 2022
Understanding MRD and What It Means for Myeloma Patients
September 30, 2022
How Should MGUS Be Monitored Over Time?
December 6, 2021
How Is Myeloma Treatment Effectiveness Monitored?
December 6, 2021
Could a Myeloma Clinical Trial Be Your Best Treatment Option?
December 6, 2021
What Is Personalized Medicine for Myeloma?
December 6, 2021
Which Myeloma Treatment Is Right for You? What You Need to Know
November 16, 2021
INSIST! Multiple Myeloma Resources
INSIST! Myeloma Resource Guide
April 28, 2023
Expert Advice for Navigating Myeloma Treatment and Care Decisions Guide
November 10, 2022
INSIST! on Better Myeloma Care Resource Guide
December 4, 2020
This program is supported by AbbVie, Bristol Myers Squibb/Celgene, Foundation Medicine, and Takeda, and through generous donations from people like you.